Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Idorsia Pharmaceuticals Ltd

Vaxxilon Ag

Claney Lebev Pereira

Peter H Seeberger

Chakkumkal Anish

Sharavathi Guddehalli Parameswarappa

Marilda Lisboa

Bopanna Monnanda

Arne Von Bonin

Naeem Khan

Benjamin Schumann

Madhu Emmadi

Christopher Martin

Subramanian Govindan

Sylvia Oestreich

Jessica Przygodda

Heung Sik Hahm

Lennart Lykke

Dominea Rathwell

Felix Bröcker

Daniel Knopp

Ju Yuel Baek

Arun Naini

Andreas Geissner

Guozhi Xiao

Paulina Kaplonek

Fei-Fei Xu

Petra Menova

Adam Calow

Adam Daniel James Calow

The present invention relates to a synthetic saccharide of general formulate (I) that is related toPS-II cell-surface polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againstbacteria.

Stable vaccine against

The present invention relates to a synthetic saccharide of general formula (I) that is related toserotype O1, O2, O2ac, and O8 O-polysaccharide and carbapenem-resistantST258 O-polysaccharide and conjugate thereof. Said synthetic saccharide, said conjugate and pharmaceutical composition containing said synthetic saccharide or said conjugate are useful for prevention and/or treatment of diseases associated with. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againstbacteria.

Vaccine against klebsiella pneumoniae

The present invention relates to a synthetic oligosaccharide of general formula (I): T*-[(—U—U—U—U—U)—(V—V—V)-T-O-L-E that is related toserotype O3, O3and/or O5 lipopolysaccharide and conjugate thereof. Said synthetic oligosaccharide, said conjugate and pharmaceutical composition containing said synthetic oligosaccharide or said conjugate are useful for prevention and/or treatment of diseases associated with. Furthermore, the synthetic oligosaccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againstserotype O3, O3and/or O5 bacteria.

Vaccine against

The present invention relates to immunogenic compositions comprising a conjugate of a saccharide fromserotype 8 and a carrier protein, and a mixture consisting of capsular polysaccharides fromserotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F individually conjugated to CRMcarrier protein, or a mixture consisting of capsular polysaccharides fromserotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F individually conjugated to a carrier protein, wherein the capsular polysaccharides fromserotypes 1, 4, 5, 6B, 7F, 9V, 14, and 23F are individually conjugated to protein D, the capsular polysaccharide fromserotype 18C is conjugated to tetanus toxoid and the capsular polysaccharide fromserotype 19F is conjugated to diphtheria toxoid. Said compositions are useful for the prevention and/or treatment of diseases caused by

Pneumococcal polysaccharide-protein conjugate composition

The present invention provides a stable synthetic saccharide of Hib polyribosylribitol-phosphate (PRP) derivative and conjugate thereof. Said saccharide, said conjugate and pharmaceutical compositions thereof are hydrolysis-resistant, long-term stable and useful for the prevention and/or treatment of diseases associated with, and more specifically of diseases associated withtype b, preferably diseases selected from meningitis, pneumonia, and epiglotitis. They have general formula (I): wherein A is formula (II) or formula (III); B is formula (IV); C is formula (V); D is formula (VI); E is formula (VII); F is formula (VIII) or formula (IX).

Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines againsttype b

The present invention relates to a synthetic saccharide of general formula (I) that is related toserotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies againsttype 2 bacteria.

Synthetic vaccines againstserotype 2

The present invention relates to synthetic saccharides of general formula (I): V*&#x2014;[U&#x2014;U&#x2014;U]&#x2014;V&#x2014;O-L-NHthat are related to carbapenem-resistantcapsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant. Furthermore, the synthetic saccharides of general formula (I): V*&#x2014;[U&#x2014;U&#x2014;U]&#x2014;V&#x2014;O-L-NHare useful as marker in immunological assays for detection of antibodies against carbapenem-resistantbacteria.

Vaccines against carbapenem-resistant

The present invention relates to well-defined synthetic saccharides of general formula (I) that are related to the repeating unit ofserotype 5 capsular polysaccharide and conjugates thereof. The conjugates and pharmaceutical compositions containing said conjugates are useful for prevention and/or treatment of diseases associated with, and more specifically against diseases associated withserotype 5. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies againstbacteria. 

Vaccines againstserotype 5

The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide oftype 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with

[object Object]

The present invention relates to synthetic saccharides of general formula (I) that are related toserotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (I) are useful as marker in immunological assays for detection of antibodies againstbacteria.

The present invention relates to synthetic saccharides of general formula (I) that are related toserotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with, and more specifically of diseases associated withserotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies againstbacteria.

The present invention provides a protein- and peptide-free conjugate comprising a synthetic carbohydrate and a carrier molecule, wherein the synthetic carbohydrate is atype 3 capsular polysaccharide related carbohydrate and the carrier molecule is a glycosphingolipid. Said conjugate and pharmaceutical composition thereof are useful for immunization against diseases associated with, and more specifically against diseases associated withtype 3.

Growing community of inventors

Berlin, Germany

Claney Lebev Pereira